← Back to Clinical Trials
Recruiting NCT06098742

Comparative Pharmacodynamics and Pharmacodynamics Equivalence of Antareit 800 mg/10 ml Oral Suspension and Riopan 800 mg Chewable Tablets in Healthy Volunteers

Trial Parameters

Condition Heartburn
Sponsor Valenta Pharm JSC
Study Type INTERVENTIONAL
Phase N/A
Enrollment 50
Sex ALL
Min Age 18 Years
Max Age 45 Years
Start Date 2024-04-25
Completion 2024-10-20
Interventions
Antareit

Brief Summary

Comparative study of the pharmacodynamic parameters and pharmacodynamic equivalence (bioequivalence) of drug Antareit 800 mg/10 ml oral suspension and drug Riopan 800 mg chewable tablets in healthy volunteers.

Eligibility Criteria

Inclusion Criteria: 1. Voluntary and handwritten informed consent form signed by a healthy volunteer to participate in the study prior to any of the study procedures; 2. Healthy male and female caucasian volunteers aged 18 to 45 years (inclusive); 3. Verified diagnosis "healthy" (without abnormal findings in the protocol-defined clinical, laboratory, and instrumental test data); 4. pH according to hourly pH-metry in the screening period, carried out at least 3 hours after the last meal, is completely in the range from 1 to 3 inclusive throughout the entire astronomical hour of measurement; 5. Blood pressure (BP) levels: 100 to 139 mm Hg, inclusive (systolic, SBP), 60 to 89 mm Hg, inclusive (diastolic, DBP); 6. Heart rate (HR) of 60 to 90 bpm, inclusive; 7. Body mass index (BMI) of 18.5 kg/m2 ≤ BMI ≤ 30 kg/m2, where the body weight range is ≥ 55 kg for men and ≥ 45 kg for women; 8. Non-smoking healthy volunteers (who have never smoked or gave up smoking more than 6 months prior to the S

Related Trials